TY - CHAP M1 - Book, Section TI - Indications for Growth Factors in Hematology-Oncology A1 - Mascara, Gerard P. A1 - Fojo, Tito A2 - Boyiadzis, Michael M. A2 - Fojo, Tito PY - 2022 T2 - Hematology-Oncology Therapy, 3e AB - EpidemiologyFebrile neutropenia is a major dose-limiting toxicity of chemotherapy. Studies have demonstrated that selective use of colony-stimulating factors (CSFs) in patients at high risk for complications of neutropenia can enhance cost-effectiveness by reducing the risk, severity, and duration of febrile neutropenia SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1187885675 ER -